Weight-loss injections, such as Mounjaro and Wegovy, have gained significant popularity, but their high cost can be a considerable financial burden. While available on the NHS for individuals with a BMI of 40 or higher, those with a BMI of 30 or more must obtain them through private channels, leading to an average 18-month treatment cost of £5,360 for Mounjaro and £3,555 for Wegovy.

However, significant savings are possible. Research by Robert Price, founder of the weight-loss drug information website SlimrChat, indicates that patients may overspend by up to £3,700 for an 18-month treatment plan if they do not compare prices across different pharmacies. Price established SlimrChat due to a perceived lack of information regarding these medications and their procurement.

Price's analysis of the market revealed substantial price disparities among online pharmacies for the same medications. For instance, a 76-week course of Mounjaro ranged from £4,656 at Dotor to £8,069 at Treated UK, a difference of £3,413. Similarly, Wegovy's lowest price was £2,418 from Medicine Market Place, while AJ Hill Aesthetics charged £6,144, an extra £3,726. These price fluctuations are attributed to fierce competition within the lucrative weight-loss drug market.

One factor contributing to higher costs is that some pharmacies may not clearly outline the total treatment expenses. Initial consultations with online pharmacies are required, followed by a review by a registered prescriber. Some providers might only state the price for the initial dose, failing to disclose that fees increase as the dosage is escalated. This makes it challenging to calculate the overall cost, especially as treatment plans typically involve gradually increasing doses over time, a process that often lasts around 18 months, as established in clinical trials.

To address this, Price developed a free calculator on SlimrChat. This tool tracks prices from over 100 online pharmacies and clinics, updating data twice weekly. It allows users to estimate the total cost of a year-long or 76-week treatment based on their projected dosage schedule. Users can input their specific dosing plan, and the calculator will identify the most cost-effective option based on current prices. The calculator also estimates potential savings if a patient were to switch suppliers to secure the lowest price for each dose, although some users may prefer the consistency of a single provider despite a potentially higher overall cost.

The calculator includes UK pharmacies registered with the General Pharmaceutical Council, ensuring they meet stringent standards. It also allows users to filter for pharmacies with high Trustpilot ratings and excludes those that hide pricing behind login pages.

Pharmacies may also offer introductory discounts, such as 10% off the first purchase or a fixed monetary amount off. While these offers can be appealing, Price warns they can lead to higher overall costs by the end of the treatment. He advises focusing on the total plan cost rather than being swayed by initial discounts, as these pharmacies may have higher prices for subsequent doses. Referral schemes also exist but should be evaluated in the context of the total expenditure.